

## 5. 510(K) SUMMARY

This 510(k) Summary is in accordance with the requirements of the Safe Medical Device Act (SMDA) of 1990. The content of this 510(k) summary is provided in conformance with 21 CFR § 807.92.

### 5.1. Submitter's Information

**Name:** Fresenius Medical Care Renal Therapies Group, LLC  
(FMC-RTG)

**Address:** 920 Winter Street  
Waltham, MA 02451-1457

**Phone:** (781) 699-4479

**Fax:** (781) 699-9635

**Contact Person:** Denise Oppermann,  
Senior Director, Regulatory Affairs - Devices

**Date of Preparation:** 01 May 2014

### 5.2. Device Name

**Trade Name:** Liberty PDx™ Cyclor

**Common Name:** System, Peritoneal, Automatic Delivery

**Classification Name:** Peritoneal dialysis system and accessories

**Classification Number:** Class II per 21 CFR §876.5630

**Product Code/Classification Panel:** FKX/Gastroenterology/Urology

### 5.3. Legally Marketed Predicate Device

Fresenius Liberty Cyclor (K123630)

### 5.4. Device Description

The Liberty PDx Cyclor is a software-controlled electromechanical device designed for use in Automated Peritoneal Dialysis (APD) therapy for the treatment of end-stage renal disease (ESRD). The Liberty PDx Cyclor is designed as a table-top unit for use with single-use, dedicated disposable set (referred to as Liberty PDx Cyclor sets). The Liberty PDx Cyclor may be prescribed for either clinical or home treatment settings, as the predicate Liberty Cyclor. Treatment settings, such as the amount of solution to be infused and the length of time the solution remains in the peritoneal cavity, are programmed into the cyclor. During treatment, the Liberty PDx Cyclor heats the

peritoneal dialysis solution prior to patient infusion, measures and delivers a predetermined amount of fluid to the patient, and monitors the drained volume.

The Liberty PDx Cyclor system consists of a Control Panel (user interface), Pump Module, Cassette Compartment, a disposable Cyclor set (single-use), IQdrive, and an optional peripheral cellular modem. The control panel consists of a touchscreen display and front panel keys which provide a user interface. The pump module consists of mushroom-head piston(s) that are linearly displaced to alternately draw the dialysate solution to and from the patient's peritoneal cavity. The cassette compartment provides the interface for the disposable cyclor set with the pump module's mushroom-head pistons. The cyclor set is connected to a number of tubes which, in turn, connect to the dialysate solution bags, the patient, or a drain and provide a flow path between the cyclor and the patient. At the end of each treatment, data generated by the Liberty PDx Cyclor and stored in battery-backed memory are read and written to a treatment data set on the IQdrive (USB memory stick). Additionally, an optional peripheral cellular modem can also be used with the Liberty PDx Cyclor to transmit treatment data files to an FTP server at the end of each treatment.

The Liberty PDx Cyclor set is loaded into the cassette compartment of the Liberty PDx Cyclor at the initiation of treatment. The cassette is composed of a ridged molded plastic (polypropylene) body covered with a flexible film/membrane. The cassette contains molded features, such as fluid channels, flexible valve domes and two (2) pumping chambers that are acted upon by the cyclor to direct the flow of the peritoneal dialysate to and from the patient's peritoneal cavity.

There are seven (7) fluid lines connected to the cassette:

- One (1) drain line
- One (1) patient connection line (with one (1) or two (2) stay•safe® patient connectors depending on the model)
- Five (5) Dialysate Solution Lines (with Safe-Lock® connector):
  - One (1) heater bag
  - One (1) last dialysate bag/'last bag option'
  - Three (3) additional solution bags

The three Liberty PDx Cyclor sets designed for use with the Liberty PDx Cyclor are constructed from identical materials. The sets differ only in the length of lines or in the number of patient connectors, as described in Table 1.

**Table 1: Liberty PDx Disposable Cyclor Sets**

Cyclor Set Product Codes	Features
050-87220	<ul style="list-style-type: none"> <li>• Dual Patient Connector</li> <li>• Patient Line - 10 feet</li> <li>• Drain Line – 28 inches</li> </ul>
050-87221	<ul style="list-style-type: none"> <li>• Single Patient Connector</li> <li>• Patient Line - 10 feet</li> <li>• Drain Line - 28 inches</li> </ul>
050-87222	<ul style="list-style-type: none"> <li>• Single Patient Connector</li> <li>• Patient Line - 20 feet</li> <li>• Drain Line - 20 feet</li> </ul>

### 5.5. Indications for Use

The Liberty PDx™ Cyclor is indicated for acute and chronic peritoneal dialysis.

### 5.6. Intended Use

The Liberty PDx™ Cyclor is intended for Automated Peritoneal Dialysis (APD) therapy for the treatment of end-stage renal disease (ESRD) in clinical and home settings. The supported peritoneal dialysis therapy types include: Continuous Cycling Peritoneal Dialysis (CCPD), Intermittent Peritoneal Dialysis (IPD), Peritoneal Dialysis Plus™ Therapy (PD+), and Tidal Peritoneal Dialysis (TPD).

### 5.7. Technological Characteristics

The Liberty PDx Cyclor system and the predicate Liberty Cyclor have equivalent technological characteristics:

1. **Fundamental Scientific Technology/Operating Principle:** Software-controlled electromechanical pumping system with actuating linear pump heads interfacing with the cassette fluid chamber to direct the flow of dialysis solution between the cyclor and the patient. Flow direction is controlled by the pump movement.
2. **Design/Configuration:** Software-controlled electromechanical device with control (pumps and valves) and monitoring (sensors) components which interface with a disposable cyclor set for fluid displacement. The single-use disposable cyclor set is comprised of dialysate fluid-contacting components such as a pump cassette assembly, male Safe-Lock connectors, tubing, and stay-safe patient connector to allow for the movement of peritoneal dialysate to and from the patient.

3. **User Interface:** Control panel with integrated touchscreen display and front panel keys.
4. **Sterility (Cyclor Set):** Ethylene oxide, fluid path only

### **5.8. Performance Data**

Performance testing requirements were determined through the application of a risk management process, applicable FDA guidance documents and performance standards (21 CFR §876.5630). Performance testing to support the determination of substantial equivalence included testing to IEC 60601-2-39:2007, ES 60601-1:2005, IEC 60601-1-2:2007, and IEC 60601-1-11:2010. The Liberty PDx Cyclor sets were tested to ISO 10993-1:2009, ISO 10993-7:2008, and ISO 11135-1:2007.

### **5.9. Conclusion**

The information provided in this submission, including design verification, risk management, electrical safety, electromagnetic compatibility (EMC), biocompatibility and usability testing demonstrates the Liberty PDx Cyclor functions as intended and supports the determination of substantial equivalence to the predicate device. Test results demonstrate that the differences between the proposed and the predicate device are not significant and do not raise any new concerns with regard to safety or effectiveness.



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center – WO66-G609  
Silver Spring, MD 20993-0002

July 30, 2014

Fresenius Medical Care Renal Therapies Group, LLC  
Denise Oppermann  
Senior Director, Regulatory Affairs - Devices  
920 Winter Street  
Waltham, MA 02451

Re: K141145  
Trade/Device Name: Liberty PDx Cyclor  
Regulation Number: 21 CFR§ 876.5630  
Regulation Name: Peritoneal dialysis system and accessories  
Regulatory Class: II  
Product Code: FKX  
Dated: May 1, 2014  
Received: May 2, 2014

Dear Denise Oppermann,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.

You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

Elaine H. Blyskun -S  
for 

Benjamin R. Fisher, Ph.D.  
Director  
Division of Reproductive, Gastro-Renal,  
and Urological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

**Indications for Use**

510(k) Number (if known)  
K141145

Device Name  
Liberty PDx Cyclor

Indications for Use (Describe)  
The Liberty PDx Cyclor is indicated for acute and chronic peritoneal dialysis.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

**PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON A SEPARATE PAGE IF NEEDED.**

**FOR FDA USE ONLY**

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
PRAStaff@fda.hhs.gov

*"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."*